We are excited to make the HER2:HER3 heterodimer
and HER3:PI3K assays available for clinical trial use, complementing the HER1 and HER3 total protein assays that are already available," said William Young, president and CEO of Monogram Biosciences.
These expanded study results are consistent with our early findings from the Rinshoken study, where medium-to-high levels of Her2 homodimers when coupled with high levels of Her3 heterodimers
, as measured by eTag assays, had a negative correlation with response," continued Dr.
However, LG100268 is non-selective in that it also activates a number of other RXR-containing heterodimers
In an effort to locate the C9 binding site on C8[alpha], truncated and chimeric C8[alpha] in which modules were deleted or exchanged for those in C8[beta] were expressed independently or as heterodimers
with C8[gamma] and combined with C8[beta].
In a large variety of tissues, RARs act by forming heterodimers
with one of the rexinoid receptors, retinoid X receptor (RXR; [alpha], [beta], or[gamma] isotypes), which bind 9-cis but not atRA (Mark et al.
Tian F, Johnson EM, Zamarripa M, Sansone S and Brancaleon L: Binding of porphyrins to tubulin heterodimers
As mentioned, it is uncertain whether the pathways for tissue-protection are activated by EPOR homodimers or heterodimers
, both, or another receptor conformation (18).
Their activation requires that they form homo- or heterodimers
with other EGFRs and trigger a series of intracellular protein kinase signalling pathways that promote cell proliferation, angiogenesis, invasion, metastasis and inhibition of apoptosis .
Some studies have shown the role of Nrf2-MafK heterodimers
in the activation of ARE-mediated gene expression (41).
Amino-acid transport by heterodimers
of 4F2hc/CD98 and members of a permease family.
Quantification of soluble HLA class I heterodimers
and beta 2-microglobulin in patients with active pulmonary tuberculosis.
Extend the Lipton Study in metastatic breast cancer by making additional VeraTag measurements, such as those for p95, HER3 and HER heterodimers
, in existing patient samples to investigate the relationship between those biomarkers and clinical outcomes, and subsequently submitting study results for presentation and publication.